In conclusion, envonalkib is effective and with a manageably safe profile in advanced ALK-positive NSCLC patients who have previously received no ALK inhibitors, significantly improving PFS compared with crizotinib, as well as reducing the risk of progression or development of brain metastases. This evidence concerns the gene ALK and non-small cell lung carcinoma.